Revisiting Our Johnson & Johnson Thesis After a 50% Rally

The prior thesis rested on three claims. First, that the Kenvue consumer-health spin cleaned up the JNJ earnings quality and made the remaining pharma-plus-medtech structure more visible to the market. Second, that the talc litigation overhang was over-discounted in the share price because the tort claim pool was narrowing as Bayer had shown with glyphosate. Third, that the Darzalex, Tremfya, and Carvykti pharma pipeline would drive 5-7% organic revenue growth through 2027 as patent headwinds on Stelara were absorbed.

Six months later, the scorecard is good. Stelara patent expiration hit harder than modelled, but Darzalex and Tremfya have grown faster than consensus, particularly in international markets. The CAR-T franchise, anchored on Carvykti, has been the standout growth contributor in the second half of 2025. Medtech has been mixed; surgery and orthopaedics are growing but electrophysiology is still digesting the Abiomed integration.

The litigation picture has not resolved. The April 17 litigation-headlines piece referenced fresh talc-related filings, which rekindled investor concerns. Our read is that the aggregate liability cap is unchanged, but the settlement path remains cloudy. This is the part of the thesis that has not progressed as we expected.

Three factors drove the repricing. One: pharma revenue growth accelerated into the second half of 2025, confirming the thesis that the Stelara loss could be absorbed. Two: the FDA approvals cadence was better than expected, with fresh indications added for Tremfya and for the CAR-T platform. Three: the macro backdrop shifted in favour of defensive compounders as inflation concerns re-emerged in early 2026.

Barclays raising the price target on 17 April is the latest marker of the sell-side pivot. The target was raised to $260 from $240, citing pharma momentum and the Carvykti ramp. Other houses had already moved; this is catch-up.

The litigation news flow has been surprisingly subdued. A small number of talc-related filings continue to emerge, and the bankruptcy-protected Red River Talc subsidiary is still the vehicle for managing the exposure. But the market has largely decided that whatever the resolution is, it will fit within the disclosed reserves. That may be optimistic; the historical pattern on mass-tort litigation is that final settlements run 30-60% above initial provisions. Bayer's glyphosate resolution is the reference. Applying that pattern to JNJ's talc reserves would imply an additional $10-15 billion of liability, or roughly 2% of the current market cap. Material but not thesis-breaking.

Net income of $26.80 billion in 2025 was up from $14.07 billion in 2024, reflecting both litigation reserve charges in the prior year base and the stronger pharma mix. On normalised earnings excluding the one-time items, the underlying growth is roughly 8% year-over-year. Free cash flow at $19.70 billion is flat, reflecting higher capex for the pharma manufacturing footprint expansion. Cash of $19.71 billion covers $47.93 billion of debt comfortably; net debt to EBITDA is approximately 1.2x, well within investment-grade parameters.

The dividend at 2.18% yield has been raised for 63 consecutive years. Dividend coverage on 2025 earnings is 45%, leaving ample capacity for buybacks. The 2025 buyback absorbed roughly $4.8 billion.

Forward P/E of 20.7x sits at the upper end of JNJ's decade range, which has spanned 15-22x. The PEG of 1.67 is fair. None of this screams 'expensive', but none of it screams 'cheap' either. This is a stock that has priced in the good news.